Navigation Links
SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012
Date:2/16/2012

BOTHELL, Wash., Feb. 16, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that it has launched several new extended-release nutritional/vitamin products based on the Company's patented oral drug delivery platform, Controlled Delivery Technology (CDT®). Eleven class-leading products are now being sold under various private label brands across the country at the nation's top retail chains. 

Each product has been designed to deliver the full nutritional or vitamin dosage over a period of time from 12 to 24 hours.  The products are available on the vitamin/nutritional supplement aisles and are easily identifiable by their 12 or 24 Hour package logo and/or Extended Release or Controlled Release nomenclature.

The Company's flagship extended release formulations are Niacin 500mg 12HR Controlled-Release, Vitamin C 1000 mg 12HR, CoQ-10 100 mg 24HR, Glucosamine Chondroitin MSM Advanced 12HR Combo, and three 24HR calcium formulations; Calcium 1200 +D with calcium citrate, Calcium + Vitamin D Plus Minerals, and Calcium + Vitamins D & K.

The Company has plans later this year to launch several new nutritional/vitamin products under its house brand SCOLR® and for additional private label products with new and existing retailers.

Stephen J. Turner, SCOLR Pharma's President and CEO, said, "This is an exciting and landmark step for SCOLR.  The acceptance by so many retailers of our nutritional products indicates there is a strong consumer demand for extended release nutritional products and vitamins. We are very enthused about the business opportunity this represents for SCOLR and our patented technologies. "

About SCOLR Pharma:
Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

Forward looking statements: 
Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward looking statements include statements regarding anticipated developments in the Company's nutritional business.  Factors that could cause these forward-looking statements to differ from actual results include delays in manufacturing, labeling or shipment of products, order revisions, or variations in retailer's marketing plans, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission.  SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Contacts:
Investor Relations:                                             
SCOLR Pharma, Inc.                                            
425.368.1050


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
2. SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products
3. SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
4. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
5. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
6. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
7. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
8. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
9. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
10. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
11. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The American Board of Family Medicine's (ABFM) Board of Directors ... Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in ... retirement at the end of 2018. Upon assuming the role of President and CEO ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):